cr.appliance experts authored and co-authored a number of scientific publications and contributed many presentations at scientific congresses and workshops.

 

Publications

 
  • Hermann R, Derendorf H, von Richter O, Rostami-Hodjegan A.
    Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. Drug-Drug and Food-Drug Interactions. J Clin Pharmacol 2018; 58: 704-16.
  • Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A.
    The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clin Pharmacokinet 2018; 56: DOI: 10.1007/s40262-018-0695-9.
  • Hermann R, Olsson B, Borgström L, Sandell D. Single Batch Bioequivalence
    Paradigm for Orally Inhaled Products: Time for Change. Clin Pharmacol Ther 2017; 103:395. doi: 10.1002/cpt.939. Epub 2017.
  • Krenn K, Lucas R, Croizé A, Boehme S, Klein KU, Hermann R, Markstaller K, Ullrich R
    Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Critical Care 2017; 21:194; DOI 10.1186/s13054-017-1795-x.
  • Hendeles L, Daley-Yates PT, Hermann R, De Backer J, Dissanayake S, Horhota ST
    Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products
    The AAPS Journal 2015; DOI: 10.1208/s12248-015-9735-7
  • Hermann R, Mungo J, Cnota P J, Ziegler D.
    Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
    Clinical Pharmacology: Advances and Applications 2014; 6: 195-204
  • Schwameis R, Eder S, Pietschmann H, Fischer B, Mascher H, Tzotzos S, Fischer H, Lucas R, Zeitlinger M, Hermann R. 
    A FIM Study to Assess Safety and Exposure of Inhaled Single Doses of AP301—A Specific ENaC Channel Activator for the Treatment of Acute Lung Injury. 
    J Clin Pharmacol 2014; 54: 341–50
  • Derendorf H, Meltzer EO, Hermann R, Canonica GW.
    Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
    Drugs of Today 2014; 50: 15-31
  • Zieglmeier M, Hermann R, Derendorf H.
    Serie Patientenorientierte Pharmazie: Ein Diabetiker mit Erysipel.
    Deutsche Apotheker Zeitung 2014; 154: 162-68
  • Hermann R, von Richter O.
    Unerwünschte Interaktionen von Phytopharmaka mit Arzneimitteln.
    DZKF 2013; 17: 42-45
  • Förster N, Hermann R, Derendorf H.
    Serie Patientenorientierte Pharmazie: Eine Patientin mit Herzrhythmusstörungen.
    Deutsche Apotheker Zeitung 2013; 153: 3392-99
  • Waltering I, Fey T, Hermann R, Derendorf H.
    Serie Patientenorientierte Pharmazie: Ein Alzheimer Patient.
    Deutsche Apotheker Zeitung 2013; 153: 2552-62
  • Hermann R, von Richter, O.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln.
    Teil 3: Gingko biloba.
    Deutsche Apotheker Zeitung 2013; 153: 2454-60
  • Richling I, Hermann R, Derendorf H.
    Verhüten ohne Risiko. Die Auwahl der passenden Methode. 
    Deutsche Apotheker Zeitung 213; 153: 1742-47
  • Richling I, Hermann R, Derendorf H.
    Eine Patientin mit Verhütungswunsch. Wahl der passenden Methode bei Thromboserisiko.
    Deutsche Apotheker Zeitung 213; 153: 1734-40
  • von Richter O, Hermann R.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln.
    Teil 2: Echinacea.
    Deutsche Apotheker Zeitung 2013; 14: 1426-1430.
  • Hermann R, von Richter O.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln.
    Teil 1: Einführung und klinische Problemstellung.
    Deutsche Apotheker Zeitung 2013; 14: 1420-1424.
  • Baumgärtner G, Zieglmeier M, Hermann R, Derendorf H.
    Einen Patientin mit Juckreiz und Ödemen.
    DAZ 2013, 153: 1056-64.
  • Hermann R.
    Arzneimittelinteraktionen mit Grapefruit
    Deutsche Apotheker Zeitung Nr. 7/2013; 38-42.
  • Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, Urbanetz N, Cittero M, Schoubben A, Hippchen C, Cade D, Fuglsang A, Morais J, Borgström L, Farshi F, Seyfang KH, Hermann R, van de Putte A, Klebovich I, Hincal A.
    Developing and advancing dry powder inhalation towards enhanced therapeutics.
    Eur J Parm Sci 2013; 48: 181-194.
  • Hermann R.
    “Gefährlicher Johanniskraut” -Wirbel um Review zu Phytopharmaka-Interaktionen.
    Deutsche Apotheker Zeitung 2012; 152: 5630-5632.
  • Förster N, Derendorf H, Hermann R. 
    Patienten Orientierte Pharmazie: Ein jugendlicher Diabetiker. 
    Deutsche Apotheker Zeitung 2012; 152: 4980-4988.
  • Krösser S, Marquet A, Gallemann D, Wolna P, Fauchoux N, Hermann R, Johne A.
    Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
    Biopharm Drug Dispos. Published online in Wiley Online Library (wileyonlinelibrary.com); 2012 Oct 24. doi:10.1002/bdd.1822.
  • Pietschmann H, Fischer H, Tzotzos S, Fischer B, Zeitlinger M, Lucas R, Hermann R, Mascher H.
    Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301.
    Eur Respir J 2012; 40 (Suppl): P4829.
  • Hermann R, von Richter O. 
    Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. 
    Planta Medica 2012; 78: 1458-1477.
  • Zieglmeier M, Derendorf H, Hermann R. 
    Patienten Orientierte Pharmazie: Eine Parkinson-Patientin mit Sturzneigung. 
    Deutsche Apotheker Zeitung 2012; 152: 3570-3575.
  • Förster N, Derendorf H, Hermann R. 
    Patienten Orientierte Pharmazie: Eine Hypertonie-Patientin. 
    Deutsche Apotheker Zeitung 2012; 152: 3088-3095.
  • Zieglmeier M, Derendorf H, Hermann R.
    Patienten Orientierte Pharmazie: Eine Schmerzpatientin. 
    Deutsche Apotheker Zeitung 2012; 2478-2486.
  • Hermann R, Cnota P, Maus J. 
    Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from randomized controlled trials. Letter to the Editors.
    Br J Clin Pharmacol 2012; 74: 207-208.
  • Evans C, Cipolla D, Chesworth T, Agurell E, Ahrens R, Conner D, Dissanayake S, Dolovich M, Doub W, Fuglsang A, Arieta A G, Golden M, Hermann R, Hochhaus G, Homes S, Lafferty P, Lyapustina S, Nair P, O’Connor D, Parkins D, Peterson I, Reisner C, Sandell D, Sing G J P, Weda M, Watson P:
    Equivalence Considerations for Orally Inhaled Products for Local Action – ISAM / IPAC-RS European Workshop Report
    J Aerosol Med Pulm Drug Deliv 2012; 25: 117-139.
  • Derendorf H, Munzel U, Petzold U, Maus J,Mascher H, Hermann R, Bousquet J. 
    Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02 – A novel aqueous nasal spray. 
    Br J Clin Pharmacol 2012; 74: 125-133.
  • Haverkamp W, Hermann R. Arzneimittelinteraktionen QT-Intervall Verlängerung und Torsade de Pointes. 
    DZKF 2012 (5/6); 16: 38-43.
  • Hermann R:
    Unerwünschte Arzneimittel-Interaktionen in Klinischer Forschung und Praxis
    DZKF 1/2 – 2011; 15: 65-70
  • Grave-Hermann K, von Richter O, Hermann R:
    The innovation crisis of the pharmaceutical industry with a particular emphasis on Germany
    Br J Clin Pharmacol 2009; 68 (Suppl. 1) 40: 74
  • Nassr N, Hünnemeyer A, Herzog R, von Richter O, Hermann R, Koch M, Duffy K, Zech K, Lahu G:
    Effects of rifampicin and roflumilast N-oxide in healthy subjects 
    Br J Clin Pharmacol 2009; 68: 580-87
  • Boehmer GM, Nassr N, Wenger M, Huennemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R.
    The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. 
    J Clin Pharmacol 2009; 49: 389-97
  • Lahu G, Huennemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, Zech K.
    Effect of repeared dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide
    J Clin Pharmacol Ther 2009; 47: 236-45.
  • Lahu G, Huennemeyer A, von Richter O, Hermann R, Herzog R, McCracken N, Zech K. 
    Effect of single and repeated ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. 
    J Clin Pharmacol 2008; 48: 1339-49.
  • Hohlfeld JM, Schoenfeld K, Mehyar Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, Krug N, Hermann R. 
    Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial. 
    Pulm Pharmacol Ther 2008; 21(4): 616-23.
  • von Richter O, Lahu G, Huennemeyer A, Zech K, Reutter F, Hermann R. 
    Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N oxide. 
    Clin Pharmacokinet 2007; 46 (7): 613-22
  • Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Reutter F, Lahu G, Zech K, Bethke TD. 
    The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with orally inhaled budesonide. 
    J Clin Pharmacol 2007; 47(8): 1005-13.
  • von Berg A, Kremer HJ, Ellers-Lenz B, Conrad F, Erb K, Maus J, Hermann R. 
    Peak inspiratory flow rates generated through the Novolizer® and the Turbuhaler® dry powder inhaler devices by children with stable asthma. 
    J Aerosol Med 2007; 20(1): 50-58.
  • Hermann R, Nassr N, Lahu G, Péterfai É, Knoerzer D, Zech K, de Mey C. 
    Steady-state pharmacokinetics of roflumilast and roflumilast N oxide in patients with mild and moderate liver cirrhosis. 
    Clin Pharmacokinet 2007; 46(5): 403-416.
  • Nassr N, Lahu G, Huennemeyer A, von Richter O, Knoerzer D, K, Reutter F, Zech K, Hermann R.
    Magnesium hydroxide / aluminium hydroxide-containing antacid Maalox® does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. 
    J Clin Pharmacol 2007; 47: 660-66.
  • Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH.
    Dose-proportional intra-individual single- and repeated-dose pharmaco-kinetics of roflumilast, an oral, once-daily phosphodiesterase 4 Inhibitor. 
    J Clin Pharmacol 2007 ; 47 : 26-36.
  • Bethke TD, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Hauschke D, David M, Zech K, Hermann R and Siegmund W.
    The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled salbutamol during co-administration in healthy subjects. 
    Int J Clin Pharmacol Ther 2006; 44:572-79.
  • Nassr N, Lahu G; von Richter O, Reutter F, Knoerzer D, Zech K, Erb K, Schug B, Blume H, Hermann R.
    Lack of pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
    Br J Clin Pharmacol 2007; 63:365-70.
  • Hauns B, Hermann R, Hünnemeyer A, Herzog R, Hauschke D, Zech K, Bethke TD.
    Investigation of a potential food effect on the pharmacokinetics of roflumilast, a once-daily, oral phosphodiesterase 4 inhibitor in healthy subjects.
    J Clin Pharmacol 2006 ; 46 : 1146-53.
  • Borlak J, Gasparic A, Locher M, Schupke H, Hermann R. 
    N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.
    Metabolism 2006; 55: 711-21.
  • Westlin-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman- Sundberg M, von Richter O.
    Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity.
    Clin Pharmacol Ther 2006; 79:339-49.
  • Hermann R, Borlak J, Munzel U, Niebch G, Fuhr U, Maus J, Erb K.
    The role of Gilbert’s syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine.
    Pharmacogenomics J 2006; 6:211-19.
  • Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R. 
    Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    J Clin Pharmacol 2005; 45:313-28.
  • Krug N, Hohlfeld JM, Geldmacher H, Larbig M, Heermann R, LaVallee N, Nguyen DT, Petzold U, Hermann R.
    Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
    Allergy 2005; 60:354-59.
  • Vogelberg C, Kremer HJ, Ellers-Lenz B, Engel M, Maus J, Conrad F, Hermann R.
    Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer.
    Resp Med 2004; 98:924-31.
  • Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G.
    Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.
    Pharmazie 2004; 59:409-11.
  • Hermann R, Locher M, Siebert-Weigel M, Lavallee N, Hochhaus G, Derendorf H.
    Placebo- and fluticasone-controlled first-in-man study with intranasal loteprednol etabonate in healthy male subjects: Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamic effects on twenty-four hour plasma cortisol secretion.
    J Clin Pharmacol 2004; 44:510-19.
  • Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Sörgel F, Fuhr U.
    Phenotyping of arylamine N-acetyltransferase type 2 by dietary caffeine metabolites.
    Eur J Clin Pharmacol 2004; 60:17-21.
  • Borlak J, Hermann R, Erb K, Thum T.
    A rapid and simple CYP2D6 genotyping assay – Case study with the analgesic tramadol.
    Metabolism 2003; 52:1439-43.
  • Teichert J, Hermann R, Ruus P, Preiss R.
    Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.
    J Clin Pharmacol 2003; 43:1257-67.
  • Schürer M, Erb K, Junge K, Schäfer HF, Schulz HU, Amschler S, Krupp S, Hermann R.
    Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothizide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets.
    Arzneim-Forsch / Drug Res 2003; 53:414-19.
  • Canonica WG, Petzold U, Kolb C, O’Keefe E, Ellers-Lenz B, Hermann R.
    Topical azelastine in perennial allergic conjunctivitis.
    Curr Med Res Opin 2003; 19:321-29.
  • Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlowa N, Litchy WJ, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D.
    SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
    Diabetes Care 2003; 26:770-76.
  • Nazarov OA, Petzold U, Haase H, Ellers-Lenz B, Hermann R.
    Azelastine eye drops in the treatment of perennial allergic conjunctivitis.
    Arzneim-Forsch / Drug Res 2003; 53:167-73.
  • Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H.
    Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women.
    J Clin Pharmacol 2003; 43:243-51.
  • Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. 
    Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. 
    Eur J Clin Pharmacol 2003; 58:795-802.
  • Hermann R, Ferron GM, Knebel N, Paul J, Richards L, Erb K, Troy S. 
    Effects of age and sex on the pharmacokinetics of retigabine. 
    Clin Pharmacol Ther 2003; 73:61-70.
  • Chuchalin AD, Kremer H-J, Metzenauer P, O’Keefe E, Hermann R. 
    Clinical equivalence trial on budesonide delivered either by the Novolizer® multidose dry powder inhaler or by the Turbuhaler® in asthmatic patients. 
    Respiration 2002; 69:502-08.
  • Erb K, Junge K, Pechstein B, Schneider E, Derendorf H, Hermann R. 
    Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. 
    J Clin Pharmacol 2002; 42:995-1001.
  • Schupke H, Hempel R, Peter G, Hermann R, Wessel K, Engel J, and Kronbach T.
    New metabolic pathways of α-lipoic acid. 
    Drug Metab Dispos 2001; 29:855-62.
  • Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R. 
    Effects on pituitary and gonadal hormones and ovulation as well as noncompartmental pharmacokinetics of single subcutaneous doses of cetrorelix acetate on a placebo-controlled study in healthy premenopausal women. 
    Fertility and Sterility 2001; 75:316-23.
  • Borlak J, Thum T, Landt O, Erb K, Hermann R.
    Molecular diagnosis of a familial nonhaemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. 
    Hepatology 2000; 32:792-95.
  • Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G, Derendorf H. 
    Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. 
    Clin Pharmacol Ther 2000; 67:617-25.
  • Erb K, Pechstein B, Schüler A, Engel J, Hermann R. 
    Pharmacodynamics and pharmacokinetics of single s.c. doses of the novel LHRH antagonist teverelix in healthy men. 
    Clin Pharmacol Ther 2000; 67:660-69.
  • Newman SP, Hirst PH, O’Keefe E, Hermann R. 
    Scintigraphic comparison of drug deposition from the ASTA Medica Bulkinhaler and the Turbuhaler. 
    Eur Respir J 2000; 16:178-83.
  • Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, Derendorf H. 
    Phamacokinetic/pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. 
    J Clin Pharmacol 2000; 40:266-74.
  • Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. 
    Oral administration of rac-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. 
    Free Radic Biol Med 1999; 27:309-14.
  • Gleiter CH, Schreeb KH, Freudenthaler S, Thomas M, Elze M, Fieger-Büschges H, Potthast H, Schneider E, Schug BS, Blume HH, Hermann R. 
    Lack of interaction between thioctic acid, glibenclamide, and acarbose. 
    Br J Clin Pharmacol 1999; 48:819-25.
  • Breithaupt-Grögler K, Niebch G, Schneider E, Erb K, Hermann R, Blume HH, Schug BS, and Belz GG.
    Dose proportionality of oral thioctic acid – coincidence of assessments via pooled plasma and individual data. 
    Eur J Pharm Sci 1999; 8:57-65.
  • Hermann R, Ruus P, Schneider E, de Mey C. 
    Tolerability and in-vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate. 
    Arzneim-Forsch / Drug Res 1998; 48:663-67.
  • Duikers IJM, Klipping C, Willemsen WNP, Krone D, Schneider E, Niebch G, Hermann R. 
    Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist cetrorelix in healthy female volunteers. 
    Human Reproduction 1998; 13:2392-98.
  • Hermann R, Heger-Mahn D, Mahler M, Seibert-Grafe M, Klipping C, Breithaupt-Grögler K,de Mey C. 
    Adverse events and discomfort in studies on healthy subjects: the volunteer’s perspective. 
    Eur J Clin Pharmacol 1997; 53:207-14.
  • Hermann R, Wildgrube HJ, Ruus P, Niebch G, Nowak H, Gleiter CH. 
    Gastric emptying in patients with IDDM and bioavailability of thioctic acid-enantiomers. 
    Eur J Pharm Sci 1998; 6:27-37.
  • Breithaupt-Grögler K, Heger-Mahn D, Klipping Ch, Butzer R, Duijkers I, Geyer D, Hermann R, Hinze Ch, Mahler M, Seiber-Grafe M. 
    Klinische Arzneimittelprüfung an Frauen. 
    Dt Ärztebl 1997; 94(35): B-794-96.
  • Rett K, Wicklmayr M, Nehrdich D, Ruus P, Hermann R, Standl E. 
    Alpha-Liponsäure steigert die Insulinempfindlichkeit insulinresistenter Patienten mit Typ-II-Diabetes. 
    Diabetes und Stoffwechsel 1996; 5 (Suppl. 3):59-63.
  • Hermann R, Niebch G, Borbe H O, Fieger H, Ruus P, Nowak H, Riethmüller-Winzen H, Peukert M. and Blume H. 
    Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. 
    Eur J Pharm Sci 1996; 4:167-74.
  • Heger-Mahn D, Mahler M, Hermann R, Nowak H, Weber W, Seibert-Grafe M. 
    Manangement of Adverse Events in Phase I trials. 
    Drugs Made in Germany 1995; 38:36-41.
  • Heger-Mahn D, Mahler M, Hermann R, Nowak H, Weber W, Seibert-Grafe M. 
    Umgang mit Unerwünschten Ereignissen in Phase-I-Prüfungen. 
    Arzneim-Forsch / Drug Res 1995; 45:331-36.
  • Heger-Mahn D, Mahler M, Hermann R, Nowak H, Weber W, Seibert-Grafe M. 
    Umgang mit Unerwünschten Ereignissen in Phase-I-Prüfungen. 
    Pharm Ind 1995; 57
  • Behne M, Lischke V, Asskali F, Probst S, Hermann R, Vettermann J. 
    Midazolam does not antagonize fentanyl-mediated analgesia in surgical patients.
    J Clin Anesth 1994; 6:481-86.:103-08.
  • Harder S, Thürmann P, Hermann R, Weller S, Mayer M. 
    Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time.
    Int J Clin Pharmacol Ther 1994; 32:577-81
  • Rosak Ch, Ziegler D, Mehnert H, Schmidt KH, Reichel G, Tetzloff W, Hermann R, Ruus P, Tritschler HJ, Ulrich H. 
    Zur lokalen Verträglichkeit intravenöser Alpha-Liponsäure. 
    Münchner Medizinische Wochenschrift (MMW) 1994; 136:142-46.
  • Farthing MJG, Alstead EM, Abrams SML, Haug G, Johnston A, Hermann R, Niebch G, Molz KH, Turner P. 
    Pharmacokinetics of naftopidil, a novel antihypertensive drug, in patients with hepatic dysfunction. 
    Postgrad Med J 1994; 70:363-66.
  • Hermann R, Vettermann J. 
    Change of ectopic supraventricular tachycardia to sinus rhythm during administration of propofol. 
    Anesth Analg 1992; 75:1030-32.
  • Lischke V, Behne M, Hermann R, Zegelmann M. 
    Changes of the QT interval in the ECG after vascular surgery at the common carotid artery. 
    Anästhesiol Intensivmed Notfallmed Schmerzther 1991; 26:252-57.
  • Hermann R, Wiederspahn-Wilz T, Voigt T, Vogelsang C, Janshon G, Becker J. 
    Combined oral and rectal premedication by midazolam – suppositories and droperidol in young children.
    Fortschr Anästh 1991; 5:15-22.
  • Hermann R, Janshon G, Eberhardt B, Becker J. 
    Midazolam for rectal premedication in children – indications for an age-dependent pharmacodynamics. 
    Fortschr Anästh 1990; 4:1-6.
  • Behne M, Hermann R, Lischke V, Lörz M. 
    Prolongation of QT interval after neck surgery (neck dissection). 
    HNO 1989; 37:449-53.
  • Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A.
    The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. Clin Pharmacokinet 2018; 56: DOI: 10.1007/s40262-018-0695-9.
  • Hermann R, Derendorf H, von Richter O, Rostami-Hodjegan A.
    Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. Drug-Drug and Food-Drug Interactions. J Clin Pharmacol 2018; 58: 704-16.
  • Derendorf H, Meltzer EO, Hermann R, Canonica GW.
    Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs of Today 2014; 50: 15-31.
  • Hermann R, von Richter O.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln. Teil 3: Ginkgo biloba. Deutsche Apotheker Zeitung 2013; 153: 2454-60.
  • Richling I, Hermann R, Derendorf H.
    Verhüten ohne Risiko. Die Auswahl der passenden Methode. Deutsche Apotheker Zeitung 2013; 153: 1742-47.
  • von Richter O, Hermann R.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln. Teil 2: Echinacea. Deutsche Apotheker Zeitung 2013; 14: 1426-1430.
  • Hermann R, von Richter O.
    Interaktion von Phytopharmaka mit konventionellen Arzneimitteln. Teil 1: Einführung und klinische Problemstellung. Deutsche Apotheker Zeitung 2013; 14: 1420-1424.
  • Hermann R.
    Arzneimittelinteraktionen mit Grapefruit. Deutsche Apotheker Zeitung 2013; 7: 3020-3024.
  • Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R, Urbanetz N, Cittero M, Schoubben A, Hippchen C, Cade D, Fuglsang A, Morais J, Borgström L, Farshi F, Seyfang KH, Hermann R, van de Putte A, Klebovich I, Hincal A.
    Developing and advancing dry powder inhalation towards enhanced therapeutics. Eur J Pharm Sci 2013; 48: 181-194.
  • Hermann R, von Richter O.
    Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Medica 2012; 78: 1458-77.
  • Evans C, Cipolla D, Chesworth T, Agurell E, Ahrens R, Conner D, Dissanayake S, Dolovich M, Doub W, Fuglsang A, Arieta A G, Golden M, Hermann R, Hochhaus G, Homes S, Lafferty P, Lyapustina S, Nair P, O’Connor D, Parkins D, Peterson I, Reisner C, Sandell D, Sing G J P, Weda M, Watson P.
    Equivalence Considerations for Orally Inhaled Products for Local Action – ISAM / IPAC-RS European Workshop Report. J Aerosol Med Pulm Drug Deliv 2012; 25: 117-139.
  • Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J, Erb K, Partiot A, Germain JM, Locher M, Porter R. Retigabine.
    Epilepsy Research 2002; 51: 36-38. In: Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Bialer M, Johanessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E.
  • Hermann R, Niebch G.
    Human pharmacokinetics of Alpha-Lipoic acid. In: Lipoic acid in health and disease. Fuchs J, Packer L, Zimmer G, Editors. Marcel Dekker, New York, 1997: Chapter 22, 337-360.
  • Engel J, Reissmann Th, Klenner Th, Hermann R, Nieschlag E, Behre HM, Hilgard P, Deger W, Sarlikiotis A.
    Sustained release formulations for long-term LHRH antagonist administration. In: Treatment with GnRH analogs: controversies and perspectives. Filicori M and Flamigni C, Editors. The Parthenon Publishing Group, New York, London, 1996: Chapter 7, 69-74.
  • Hermann R, Gleiter CH, Niebch G, Ruus P, Wildgrube HJ, Nowak H.
    Alpha-Lipoic acid – current state of the enantioselective pharmacokinetics in healthy volunteers and diabetic patients. Diabetes und Stoffwechsel 1996; 5 (Suppl 3): 5-11.
  • Krauser K, Schneider E, Hermann R, Jahn W.
    Aesthesiometry – azelastine eye drops reduce corneal sensitivity in rabbits, but not in dogs and humans. In: Ocular Toxicology. Weisse I et. al., Editors. Plenum Press, New York, 1995: 287-295.
  • Hermann R, Olsson B, Borgström L, Sandell D.
    Single Batch Bioequivalence Paradigm for Orally Inhaled Products: Time for Change. Clin Pharmacol Ther 2017; 103:395. doi: 10.1002/cpt.939. Epub 2017.
  • Zieglmeier M, Hermann R Derendorf H.
    Serie Patienten Orientierte Pharmazie: Ein Diabetiker mit Erisypel. Deutsche Apotheker Zeitung 2014; 154: 162-68.
  • Förster N, Hermann R, Derendorf H.
    Serie Patienten Orientierte Pharmazie: Eine Patientin mit Herzrhythmusstörungen. Deutsche Apotheker Zeitung 2013; 153: 3392-99.
  • Waltering I, Fey T, Hermann R, Derendorf H.
    Serie Patienten Orientierte Pharmazie: Ein Alzheimer-Patient. Deutsche Apotheker Zeitung 2013; 153: 2552-62.
  • Richling I, Hermann R, Derendorf H.
    Serie Patienten Orientierte Pharmazie: Eine Patientin mit Verhütungswunsch. Wahl der passenden Methode bei Thromboserisiko. Deutsche Apotheker Zeitung 2013; 153: 1734-40.
  • Baumgärtner G, Zieglmeier M, Hermann R Derendorf H.
    Serie Patienten Orientierte Pharmazie: Eine Patientin mit Juckreiz und Ödemen. Deutsche Apotheker Zeitung 2013; 153: 1056-64.
  • Hermann R.
    „Gefährliches Johanniskraut“ – Wirbel um Review zu Phytopharmaka-Interaktionen. Deutsche Apotheker Zeitung 2012; 152: 5630-32.
  • Förster N, Derendorf H, Hermann R.
    Serie Patienten Orientierte Pharmazie: Ein jugendlicher Diabetiker. Deutsche Apotheker Zeitung 2012; 152: 4980-88.
  • Zieglmeier M, Derendorf H, Hermann R.
    Serie Patienten Orientierte Pharmazie: Eine Parkinson-Patientin mit Sturzneigung. Deutsche Apotheker Zeitung 2012; 152: 3000-05.
  • Förster N, Derendorf H, Hermann R.
    Serie Patienten Orientierte Pharmazie: Eine Hypertonie-Patientin. Deutsche Apotheker Zeitung 2012; 152: 3088-95.
  • Zieglmeier M, Derendorf H, Hermann R.
    Serie Patienten Orientierte Pharmazie: Eine Schmerzpatientin. Deutsche Apotheker Zeitung 2012; 152: 2478-86.
  • Hermann R, Cnota P, Maus J.
    Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from randomized controlled trials. Br J Clin Pharmacol 2012; 74: 207-208.
  • Gleiter CH, Schug BS, Hermann R, Elze M, Blume HH, Gundert-Remy U.
    Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol 1996; 50:513-514.
  • Schlag R, Hermann R.
    Schwere Nebenwirkungen durch Mesna. Dt. Ärztebl. 1991; 88: Heft 43/35 (45) B-1893-94.

 

Abstracts / Posters

More than 75 Abstracts and Poster Presentations from 1989 to date (List available on request).